BridgeMD
A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolving film for treatment of acute allergic reaction
EU CTIS ID: 2023-504975-25-00
What this study is testing
To evaluate the patient’s overall satisfaction with having access to Zeqmelit™ 6 mg in relation to the patient’s standard treatment overall, and in case of an acute allergic reaction.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female patients ≥ 18 years of age, willing and able to give written informed consent for participating in the trial who previously have experienced acute allergic reactions and who is currently prescribed betamethasone tablets for treatment of such reactions.
You likely can't join if
- Patient who cannot handle a web-based eDiary via their own electronic device (phone, tablet).
- Patients with other medical conditions that in the opinion of the Investigator would exclude the patient from trial participation.
- Patients who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.